Molecular Imaging of the Lung - Phase 2 (R01)

The summary for the Molecular Imaging of the Lung - Phase 2 (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Molecular Imaging of the Lung - Phase 2 (R01): This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to develop novel in vivo imaging technologies using molecular probes that target pathways or cells involved in the pathobiology of pulmonary diseases. The long-term goal of this program is to develop novel molecular imaging entities and approaches that facilitate early detection and diagnosis of lung disease, enable noninvasive monitoring of lung disease progression and prognosis, and accelerate progress of cell-specific drug delivery and therapies.The previous FOA (RFA-HL-12-036 - Phase 1) supported projects to develop and validate innovative novel imaging agents and approaches that included target selection, probe development and production, and initial characterization of the probe. Phase 2 of this initiative will support studies that advance translation of identified probes and associated imaging approaches from animal models into applicability for human lung diseases. Phase 2 studies must include work performed in vivo using appropriate animal models of lung diseaseand studies using human tissues and/or cells. Applications proposing Investigational New Drug (IND)-enabling studies of novel probes and imaging approaches are encouraged. Applicants are not required to have been funded in Phase 1 (RFA-HL-12-036) in order to submit applications for Phase 2.

Federal Grant Title:	Molecular Imaging of the Lung - Phase 2 (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-16-001
Type of Funding:	Grant
CFDA Numbers:	93.838
CFDA Descriptions:	Lung Diseases Research
Current Application Deadline:	Jun 15, 2015
Original Application Deadline:	Jun 15, 2015
Posted Date:	Mar 17, 2015
Creation Date:	Mar 17, 2015
Archive Date:	Jul 16, 2015
Total Program Funding:	$3,500,000
Maximum Federal Grant Award:	$450,000
Minimum Federal Grant Award:	none
Expected Number of Awards:	5
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
County governments
Small businesses
Public and State controlled institutions of higher education
Independent school districts
State governments
Private institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Special district governments
For profit organizations other than small businesses
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-16-001.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Viral INfections in the Young Lung- The VINYL Clinical Consortium- Data Analytics and Coor...; • Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial ...; • Limited Competition: Physician Scientist Transition to Independence in Blood Science Resea...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordi...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissu...; • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models; • Lung Response to Inhaled Highly Toxic Chemicals; • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
More Grants from the National Institutes of Health: • Cellular Senescence Network (SenNet): SenNet Data Coordination and Integration Center (Sen...; • Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed); • Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory ...; • Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARR...; • Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials N...